Radar Therapeutics

Ownership

Private

Therapeutic Areas

Other

Stage

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

mRNA-based therapeuticsprogrammable genetic medicines

Radar Therapeutics General Information

Radar Therapeutics has demonstrated proof-of-concept for its programmable mRNA therapies in preclinical settings. Their technology enables cell-specific expression of therapeutic payloads by sensing endogenous RNA markers, aiming to avoid off-target effects and improve safety. No human clinical results have been reported yet

Contact Information

Website

https://radartx.bio/

Primary Industry

Biotech

Corporate Office

Berkeley, California
United States

Drug Pipeline

No pipeline data available

For full access to Radar Therapeutics's pipeline data

Book a demo

Key Partnerships

No major pharmaceutical partnerships disclosed as of May 2024. The company has received industry recognition/awards from AbbVie, J&J West Coast Cell & Gene Therapy Symposium, and Amgen Diversity Initiative

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Radar Therapeutics Funding

Deal Type	Date	Amount	Status	Stage
Investment	May 23, 2024	$13.4M	Completed	Preclinical

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view Radar Therapeutics's complete valuation and funding history, request access »